An estimate of the course of herpes simplex virus encephalitis.
Serologic responses, physical findings, and survival were studied in 51 cases of proved (14 patients) or presumptive (37 patients) herpes simplex encephalitis occurring in North America between 1965 and 1972. On the basis of a statistical analysis of 16 serological parameters tested in both groups, presumptive cases are likely similar to definitive cases. Using this assumption, the following tentatives conclusions are possible. Complement-fixing antibodies may be more sensitive measures of rises in anti-herpes simplex virus antibodies than are conventional or complement-requiring neutralizing or passive hemagglutinating antibodies. Mortality in herpes simplex virus encephalitis may vary from 0 to 80% and may be predictable depending upon the occurrence of seizures, paralysis and coma. Coma seems to dictate the dour prognosis. When 51 cases of herpes simplex virus encephalitis reported in the literature by others between 1944 and 1972 were analyzed by this method, a comparably varied mortality was obtained. It did not appear that treatment with idoxuridine increased the likelihood of survival.
D000914:Antibodies, Viral / Q000032:analysis; D003128:Coma; D004660:Encephalitis / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D005260:Female; D006561:Herpes Simplex / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D008297:Male; D010243:Paralysis; D018139:Simplexvirus / Q000276:immunology
D000914:Antibodies, Viral; D007065:Idoxuridine